Effects of hypertension on cancer survival: A meta-analysis.
cancer
hypertension
meta-analysis
survival
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
03
01
2021
received:
17
11
2020
accepted:
16
01
2021
pubmed:
21
1
2021
medline:
31
12
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
Hypertension is usually associated with increased cardiovascular mortality. Uncertainty exists about the possible role of hypertension as a poor prognostic factor for cancer-specific mortality (CSM). To assess the association between pre-existing hypertension and the risk of mortality and relapse after a diagnosis of cancer, we performed a systematic review and meta-analysis of published studies. PubMed, Scopus, Web of Science, the Cochrane Library and EMBASE were searched from inception until May 2020, without language restrictions, for observational studies reporting the prognosis of patients with hypertension and cancer. The primary outcome of the study refers to CSM in hypertensive vs nonhypertensive patients, and secondary endpoints were overall mortality (OM) and progression- or relapse-free survival. The effect size was reported as hazard ratios (HRs) with 95% CIs. Mortality and relapse associated with hypertension in patients with various cancers were evaluated among 1 603 437 participants (n = 66 studies). Overall, diagnosis of cancer and hypertension was associated with an increased independent risk of OM (HR = 1.2 [95% CI, 1.13-1.27], P < .01) and CSM (HR = 1.12 [95% CI, 1.04-1.21], P < .01) but not of relapse (HR = 1.08 [95% CI, 0.98-1.19], P = .14). Among cancer patients, those with pre-existing hypertension have a poorer outcome, probably due to multifactorial reasons. Adequate control of lifestyle, more intensive follow-ups, monitoring for hypertension- and anticancer-related cardiovascular complications, and establishing multidisciplinary cardio-oncology units can be useful measures for reducing mortality and improving care in this setting.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertension is usually associated with increased cardiovascular mortality. Uncertainty exists about the possible role of hypertension as a poor prognostic factor for cancer-specific mortality (CSM). To assess the association between pre-existing hypertension and the risk of mortality and relapse after a diagnosis of cancer, we performed a systematic review and meta-analysis of published studies.
METHODS
METHODS
PubMed, Scopus, Web of Science, the Cochrane Library and EMBASE were searched from inception until May 2020, without language restrictions, for observational studies reporting the prognosis of patients with hypertension and cancer. The primary outcome of the study refers to CSM in hypertensive vs nonhypertensive patients, and secondary endpoints were overall mortality (OM) and progression- or relapse-free survival. The effect size was reported as hazard ratios (HRs) with 95% CIs.
RESULTS
RESULTS
Mortality and relapse associated with hypertension in patients with various cancers were evaluated among 1 603 437 participants (n = 66 studies). Overall, diagnosis of cancer and hypertension was associated with an increased independent risk of OM (HR = 1.2 [95% CI, 1.13-1.27], P < .01) and CSM (HR = 1.12 [95% CI, 1.04-1.21], P < .01) but not of relapse (HR = 1.08 [95% CI, 0.98-1.19], P = .14).
CONCLUSIONS
CONCLUSIONS
Among cancer patients, those with pre-existing hypertension have a poorer outcome, probably due to multifactorial reasons. Adequate control of lifestyle, more intensive follow-ups, monitoring for hypertension- and anticancer-related cardiovascular complications, and establishing multidisciplinary cardio-oncology units can be useful measures for reducing mortality and improving care in this setting.
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13493Informations de copyright
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Gijón-Conde T, Sánchez-Martínez M, Graciani A, et al. Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals. J Hypertens. 2019;37(7):1393-1400.
Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015-2016. NCHS Data Brief. 2017;289:1-8.
Chen P, Zhang W, Wang X, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Med [Internet]. 2015;94(33):e1260. https://doi.org/10.1038/srep31358
Han H, Guo W, Shi W, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep [Internet]. 2017;7:1-9. https://doi.org/10.1038/srep44877
Uzunlulu M, Telci Caklili O, Oguz A. Association between metabolic syndrome and cancer. Ann Nutr Metab. 2016;68:173-179.
Yang X, Wang J. The role of metabolic syndrome in endometrial cancer: a review. Front Oncol [Internet]. 2019;9:1-14.Available from https://www.frontiersin.org/articles/10.3389/fonc.2019.00744
Jawa Z, Perez RM, Garlie L, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (United States). 2016;95:e5195.
Li J, Gu J. Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials. Clin Drug Invest. 2018;38(12):1109-1123.
Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479-486.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2010;283(15):2008-2011.
Cook DA, Reed DA. Appraising the quality of medical education research methods: The Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. Acad Med. 2015;90(8):1067-1076.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(7829):d5928.
Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol. 2019;1(2):238-251.
Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899-1911.
Dal Moro F, Bovo A, Crestani A, Vettor R, Gardiman MP, Zattoni F. Effect of hypertension on outcomes of high-risk patients after BCG-treated bladder cancer. Med (United States). 2015;94(9):e589.
Zeng X, Zeng D, Cheng J, et al. Influence of hypertension on the survival of non-small cell lung cancer patients with type 2 diabetes mellitus. Med Sci Monit. 2020;26:e921676.
Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Am J Cardiol. 2020;125(12):1920-1926.
Kenzik KM, Balentine C, Richman J, Kilgore M, Bhatia S, Williams GR. New-onset cardiovascular morbidity in older adults with stage i to III colorectal cancer. J Clin Oncol. 2018;36(6):609-616.
Kravchenko J, Berry M, Arbeev K, Kim Lyerly H, Yashin A, Akushevich I. Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis. Lung Cancer. 2015;88(1):85-93.
Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34(10):1122-1130.
Williams GR, Deal AM, Lund JL, et al. Patient-reported comorbidity and survival in older adults with cancer. Oncologist. 2017;23(4):433-439.
Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008;54(4):816-823.
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815.
Hershman DL, McBride RB, Eisenberger A, Wei YT, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(19):3159-3165.
Salz T, Zabor EC, de Brown P, et al. Preexisting cardiovascular risk and subsequent heart failure among non-hodgkin lymphoma survivors. J Clin Oncol. 2017;35(34):3837-3843.
Takamochi K, Oh S, Matsuoka J, Suzuki K. Risk factors for morbidity after pulmonary resection for lung cancer in younger and elderly patients. Interact Cardiovasc Thorac Surg. 2011;12(5):739-743.
Yang Y, Li HY, Zhou Q, et al. Renal function and all-cause mortality risk among cancer patients. Med (United States). 2016;95(20):1-8.
Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K. Mortality causes in cancer patients with type 2 diabetes mellitus. Eur J Cancer Prev. 2012;21(3):300-306.
Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-636.
Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type, 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol. 2011;29(22):3001-3007.
Teo KK. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens. 2011;29(4):623-635.
Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis. 2005;26(2):271-279.
Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112(1):67-75.
Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017;70(20):2536-2551.
Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997-e1012.